Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS - Institutional Research Information System IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.
IRInSubria - Institutional Repository Insubria IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701)
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
Huisman M. V.;Rothman K. J.;Paquette M.;Teutsch C.;Diener H. -C.;Dubner S. J.;Halperin J. L.;Ma C. S.;Zint K.;Elsaesser A.;Bartels D. B.;Lip G. Y. H.;Abban D.;Abdul N.;Abelson M.;Ackermann A.;Adams F.;Adams L.;Adragao P.;Ageno W.;Aggarwal R.;Agosti S.;Marin J. A.;Aguilar F.;Aguilar Linares J. A.;Aguinaga L.;Ahmad Z.;Ainsworth P.;Al Ghalayini K.;Al Ismail S.;Alasfar A.;Alawwa A.;Al-Dallow R.;Alderson L.;Alexopoulos D.;Ali A.;Ali M.;Aliyar P.;Al-Joundi T.;Al Mahameed S.;Almassi H.;Almuti K.;Al-Obaidi M.;Alshehri M.;Altmann U.;Alves A. R.;Al-Zoebi A.;Amara W.;Amelot M.;Amjadi N.;Ammirati F.;Andrawis N.;Angoulvant D.;Annoni G.;Ansalone G.;Antonescu S. A.;Ariani M.;Arias J. C.;Armero S.;Arora R.;Arora C.;Ashcraft W.;Aslam M. S.;Astesiano A.;Audouin P.;Augenbraun C.;Aydin S.;Azar R.;Azim A.;Aziz S.;Backes L. M.;Baig M.;Bains S.;Bakbak A.;Baker S.;Bakhtiar K.;Bala R.;Banayan J.;Bandh S.;Bando S.;Banerjee S.;Bank A.;Barbarash O.;Baron G.;Barr C.;Barrera C.;Barton J.;Kes V. B.;Baula G.;Bayeh H.;Bazargani N.;Behrens S.;Bell A.;Benezet-Mazuecos J.;Benhalima B.;Berdague P.;Berg van den B. J.;Bergen van P. F. M. M.;Berngard E.;Bernstein R.;Berrospi P.;Berti S.;Bertomeu V.;Berz A.;Bettencourt P.;Betzu R.;Beyer-Westendorf J.;Bhagwat R.;Black T.;Blanco Ibaceta J. H.;Bloom S.;Blumberg E.;Bo M.;Bockisch V.;Bohmer E.;Bongiorni M. G.;Boriani G.;Bosch R.;Boswijk D. J.;Bott J.;Bottacchi E.;Kalan M. B.;Brandes A.;Bratland B.;Brautigam D.;Breton N.;Brouwers P. J. A. M.;Browne K.;Bruguera J.;Brunehaut M.;Brunschwig C.;Buathier H.;Buhl A.;Bullinga J.;Butcher K.;Cabrera Honorio J. W.;Caccavo A.;Cadinot D.;Cai S.;Calvi V.;Camm J.;Candeias R.;Capo J.;Capucci A.;Cardoso J. N.;Duarte Vera Y. C.;Carlson B.;Carvalho P.;Cary S.;Casanova R.;Casu G.;Cattan S.;Cavallini C.;Cayla G.;Cha T. J.;Cha K. S.;Chaaban S.;Chae J. K.;Challappa K.;Chand S.;Chandrashekar H.;Chang M.;Charbel P.;Chartier L.;Chatterjee K.;Cheema A.;Chen S. -A.;Chevallereau P.;Chiang F. -T.;Chiarella F.;Chih-Chan L.;Cho Y. K.;Choi D. J.;Chouinard G.;Danny;Chow H. F.;Chrysos D.;Chumakova G.;Jose Roberto Chuquiure Valenzuela E. J.;Cieza-Lara T.;Nica V. C.;Ciobotaru V.;Cislowski D.;Citerne O.;Claus M.;Clay A.;Clifford P.;Cohen S.;Cohen A.;Colivicchi F.;Collins R.;Compton S.;Connors S.;Conti A.;Buenostro G. C.;Coodley G.;Cooper M.;Corbett L.;Corey O.;Coronel J.;Corrigan J.;Cotrina Pereyra R. Y.;Cottin Y.;Coutu B.;Cracan A.;Crean P.;Crenshaw J.;Crijns H. J. G. M.;Crump C.;Cucher F.;Cudmore D.;Cui L.;Culp J.;Darius H.;Dary P.;Dascotte O.;Dauber I.;Davee T.;Davies R.;Davis G.;Davy J. -M.;Dayer M.;De La Briolle A.;de Mora M.;De Teresa E.;De Wolf L.;Decoulx E.;Deepak S.;Defaye P.;Del-Carpio Munoz F.;Brkljacic D. D.;Deluche L.;Destrac S.;Deumite N. J.;Di Legge S.;Dibon O.;Diemberger I.;Dillinger J.;Dionisio P.;Naydenov S.;Dotani I.;Dotcheva E.;D'Souza A.;Dubrey S.;Ducrocq X.;Dupljakov D.;DuThinh V.;Dutra O. P.;Dutta D.;Duvilla N.;Dy J.;Dziewas R.;Eaton C.;Eaves W.;Ebinger M.;Eck van J. W. M.;Edwards T.;Egocheaga I.;Ehrlich C.;Eisenberg S.;El Hallak A.;El Jabali A.;El Mahmoud R.;El Shahawy M.;Eldadah Z.;Elghelbazouri F.;Elhag O.;El-Hamdani M.;Elias D.;Ellery A.;El-Sayed H.;Elvan A.;Erickson B.;Espaliat E.;Essandoh L.;Everington T.;Evonich R.;Ezhov A.;Facila L.;Farsad R.;Fayard M.;Fedele F.;Gomes Ferreira L. G.;Ferreira D.;Santos J. F.;Ferrier A.;Finsen A.;First B.;Fisher R.;Floyd J.;Folk T.;Fonseca C.;Fonseca L.;Forman S.;Forsgren M.;Foster M.;Foster N.;Frais M.;Frandsen B.;Frappe T.;Freixa R.;French W.;Freydlin M.;Frickel S.;Fruntelata A. G.;Fujii S.;Fujino Y.;Fukunaga H.;Furukawa Y.;Gabelmann M.;Gabris M.;Gadsboll N.;Galin P.;Galinier M.;Ganim R.;Garcia R.;Quintana A. G.;Gartenlaub O.;Genz C.;Georger F.;Georges J. -L.;Georgeson S.;Ghanbasha A.;Giedrimas E.;Gierba M.;Gillespie E.;Giniger A.;Gkotsis A.;Gmehling J.;Gniot J.;Goethals P.;Goldberg R.;Goldmann B.;Goldscher D.;Golitsyn S.;Gomez Lopez E. A.;Gomez Mesa J. E.;Gonzalez E.;Cocina E. G.;Juanatey C. G.;Gorbunov V.;Gordon B.;Gorka H.;Gornick C.;Gorog D.;Goss F.;Gotte A.;Goube P.;Goudevenos I.;Goulden D.;Graham B.;Grande A.;Greco C.;Green M.;Greer G.;Gremmler U.;Grena P.;Grinshstein Y.;Grond M.;Gronda E.;Grondin F.;Gronefeld G.;Groot de J. R.;Guardigli G.;Guarnieri T.;Caiedo C. G.;Guignier A.;Gulizia M.;Gumbley M.;Gupta D.;Hack T.;Haerer W.;Hakas J.;Hall C.;Hampsey J.;Hananis G.;Hanbali B.;Handel F.;Hargrove J.;Hargroves D.;Harris K.;Hartley D.;Haruna T.;Hata Y.;Hayek E.;Healey J.;Hearne S.;Heggelund G.;Hemels M. E. W.;Hemery Y.;Henein S.;Henz B.;Her S. -H.;Hermany P.;Hernandes M. E.;Higashino Y.;Hill M.;Hisadome T.;Hishida E.;Hitchcock J.;Hoffer E.;Hoghton M.;Holmes C.;Hong S. K.;Houppe Nousse M. -P.;Howard V.;Hsu L. F.;Huang C. -H.;Huckins D.;Huehnergarth K.;Huizenga A.;Huntley R.;Hussein G.;Hwang G. -S.;Igbokidi O.;Iglesias I.;Ikpoh M.;Imberti D.;Ince H.;Indolfi C.;Ionova T.;Ip J.;Irles D.;Iseki H.;Ismail Y.;Israel N.;Isserman S.;Iteld B.;Ivanchura G.;Iyer R.;Iyer V.;Iza Villanueva R. O.;Jackson-Voyzey E.;Jaffrani N.;Jager F.;Jain M.;James M.;Jamon Y.;Jang S. W.;Pereira Jardim C. A.;Jarmukli N.;Jeanfreau R.;Jenkins R.;Jiang X.;Jiang H.;Jiang T.;Jiang N.;Jimenez J.;Jobe R.;Joffe I.;Johansson B.;Jones N.;Moura Jorge J. C.;Jouve B.;Jundi M.;Jung W.;Jung B. C.;Jung K. T.;Kabbani S.;Kabour A.;Kafkala C.;Kajiwara K.;Kalinina L.;Kampus P.;Kanda J.;Kapadia S.;Karim A.;Karolyi L.;Kashou H.;Kastrup A.;Katsivas A.;Kaufman E.;Kawai K.;Kawajiri K.;Kazmierski J.;Keeling P.;Kerfes G. A.;Kerr Saraiva J. F.;Ketova G.;Khaira A.;Khalid M.;Khludeeva E.;Khripun A.;Kim D. I.;Kim D. K.;Kim N. H.;Kim K. S.;Kim Y. -H.;Kim J. B.;Kim J. S.;Kim J. S.;Kinova E.;Klein A.;Kleinschnitz C.;Kmetzo J.;Kneller G. L.;Knezevic A.;Koch S.;Koenig K.;Angela Koh S. M.;Kohrmann M.;Koons J.;Korabathina R.;Korennova O.;Koschutnik M.;Kosinski E.;Kovacic D.;Kowalczyk J.;Koziolova N.;Kragten J. A.;Krause L. U.;Kreidieh I.;Krenning B. J.;Krishnaswamy K.;Krysiak W.;Kuck K. -H.;Kumar S.;Kumler T.;Kuniss M.;Kuo J. -Y.;Kuppers A.;Kurrelmeyer K.;Kwan T.;Kyo E.;Labovitz A.;Lacroix A.;Lam A.;Lanas Zanetti F. T.;Landau C.;Landini G.;Lang W.;Larsen T. B.;Laske V.;Lavandier K.;Law N.;Lee M. H.;Lee D.;Leitao A.;Lejay D.;Lelonek M.;Lenarczyk R.;Leprince P.;Lequeux B.;Leschke M.;Ley N.;Li Z.;Li Y.;Li X.;Li Z.;Li W.;Liang J.;Lieber I.;Lillestol M.;Limon Rodriguez R. H.;Lin H.;Lip G.;Litchfield J.;Liu Z.;Liu X.;Liu Y.;Liu F.;Liu W.;Llamas Esperon G. A.;Llisterri J. L.;Lo T.;Lo E.;Lobos J. M.;Lodde B. -P.;Loiselet P.;Lopez-Sendon J.;Lorga Filho A. M.;Lori I.;Luo M.;Lupovitch S.;Lyrer P.;Zuhairy H. M.;Ma C.;Ma G.;Ma H.;Madariaga I.;Maeno K.;Magnin D.;Mahmood S.;Mahood K.;Maid G.;Mainigi S.;Makaritsis K.;Maldonado Villalon J. A.;Malhotra R.;Malik A.;Mallecourt C.;Mallik R.;Manning R.;Manolis A.;Mantas I.;Manzur Jattin F. G.;Marcionni N.;Marin F.;Santana A. M.;Martinez J.;Martinez L.;Maskova P.;Hernandez N. M.;Matskeplishvili S.;Matsuda K.;Mavri A.;May E.;Mayer N.;Mazon P.;McClure J.;McCormack T.;McGarity W.;McGuire M.;McIntyre H.;McLaughlin P.;McLaurin B.;Medina Palomino F. A.;Mehta P.;Mehzad R.;Meinel A.;Melandri F.;Mena A.;Meno H.;Menzies D.;Metcalf K.;Meyer B.;Miarka J.;Mibach F.;Michalski D.;Michel P.;Chreih R. M.;Mikdadi G.;Mikhail M.;Mikus M.;Milicic D.;Militaru C.;Miller G.;Milonas C.;Minescu B.;Mintale I.;Miralles A.;Mirault T.;Mistry D.;Mitchell G.;Miu N. V.;Miyamoto N.;Moccetti T.;Mohammed A.;Nor A. M.;Molina de Salazar D. I.;Molon G.;Molony D.;Mondillo S.;Mont L.;Moodley R.;Moore R.;Ribeiro Moreira D. A.;Mori K.;Moriarty A.;Morka J.;Moschos N.;Mota Gomes M. A.;Mousallem N.;Moya A.;Mugge A.;Mulhearn T.;Muller J. -J.;Muresan C. M.;Muse D.;Musial W.;Musumeci F.;Nadar V.;Nageh T.;Nair P.;Nakagawa H.;Nakamura Y.;Nakayama T.;Nam K. -B.;Napalkov D.;Natarajan I.;Nayak H.;Nechvatal L.;Neiman J.;Nerheim P.;Neuenschwander F. C.;Nishida K.;Nizov A.;Novikova T.;Novo S.;Nowalany-Kozielska E.;Nsah E.;Nunez Fragoso J. C.;Nyvad O.;de Los Rios Ibarra M. O.;O'Donnell M.;O'Donnell P.;Oh D. J.;Oh Y. S.;Daniel Oh C. T.;O'Hara G.;Oikonomou K.;Olalla J. J.;Olivari Z.;Oliver R.;Olympios C.;Osborne J.;Osca J.;Osman R.;Osunkoya A.;Padanilam B.;Panchenko E.;Pandey A. S.;Vicenzo de Paola A. A.;Paraschos A.;Pardell H.;Park H. W.;Park J. S.;Parkash R.;Parker I.;Parrens E.;Parris R.;Passamonti E.;Patel J.;Patel R.;Pentz W. H.;Persic V.;Perticone F.;Peters P.;Petkar S.;Pezo L. F.;Pham D.;Cao Phai G. P.;Phlaum S.;Pineau J.;Pineda-Velez A.;Pini R.;Pinter A.;Pinto F.;Pirelli S.;Pivac N.;Pizzini A. M.;Pocanic D.;Calin Podoleanu C. G.;Polanczyk C. A.;Polasek P.;Poljakovic Z.;Pollock S.;Polo J.;Poock J.;Poppert H.;Porro Y.;Pose A.;Poulain F.;Poulard J. -E.;Pouzar J.;Povolny P.;Pozzer D.;Pras A.;Prasad N.;Prevot S.;Protasov K.;Prunier L.;Puleo J.;Pye M.;Qaddoura F.;Quedillac J. -M.;Raev D.;Rahimi S.;Raisaro A.;Rama B.;Ranadive N.;Randall K.;Ranjith N.;Raposo N.;Rashid H.;Raters C.;Rauch-Kroehnert U.;Rebane T.;Regner S.;Renzi M.;Reyes Rocha M. A.;Reza S.;Ria L.;Richter D.;Rickli H.;Rickner K.;Rieker W.;Rigo F.;Ripoll T.;Fonteles Ritt L. E.;Roberts D.;Pascual C. R.;Briones I. R.;Reyes H. R.;Roelke M.;Roman M.;Romeo F.;Ronner E.;Ronziere T.;Rooyer F. A.;Rosenbaum D.;Roth S.;Rozkova N.;Rubacek M.;Rubalcava F.;Rubanenko O.;Rubin A.;Borret M. R.;Rybak K.;Sabbour H.;Morales O. S.;Sakai T.;Salacata A.;Salecker I.;Salem A.;Salfity M.;Salguero R.;Salvioni A.;Samson M.;Sanchez G.;Sandesara C.;Saporito W. F.;Sasaoka T.;Sattar P.;Savard D.;Scala P. -J.;Scemama J.;Schaupp T.;Schellinger P.;Scherr C.;Schmitz K. -H.;Schmitz B.;Schmitz L.;Schnitzler R.;Schnupp S.;Schoeniger P.;Schon N.;Schuster S.;Schwimmbeck P.;Seamark C.;Seebass R.;Seidl K. -H.;Seidman B.;Sek J.;Sekaran L.;Seko Y.;Sepulveda Varela P. A.;Sevilla B.;Shah V.;Shah A.;Shah N.;Shah A.;Shanes J.;Sharareh A.;Sharma V. K.;Shaw L.;Shimizu Y.;Shimomura H.;Shin D. G.;Shin E. -S.;Shite J.;Shoukfeh M.;Shoultz C.;Silver F.;Sime I.;Simmers T. A.;Singal D.;Singh N.;Siostrzonek P.;Sirajuddin M.;Skeppholm M.;Smadja D.;Smith R.;Smith D.;Soda H.;Sofley C. W.;Sokal A.;Sotolongo R.;de Souza O. F.;Sparby J. A.;Spinar J.;Sprigings D.;Spyropoulos A.;Stakos D.;Steinberg A.;Steinwender C.;Stergiou G.;Stites H. W.;Stoikov A.;Strasser R.;Streb W.;Styliadis I.;Su G.;Su X.;Suarez R. M.;Sudnik W.;Sueyoshi A.;Sukles K.;Sun L.;Suneja R.;Svensson P.;Ziekenhuis A.;Szavits-Nossan J.;Taggeselle J.;Takagi Y.;Takhar A.;Tallet J.;Tamm A.;Tanaka S.;Tanaka K.;Tang A.;Tang S.;Tassinari T.;Tayama S.;Tayebjee M.;Tebbe U.;Teixeira J.;Tesloianu D. N.;Tessier P.;The S. H. K.;Thevenin J.;Thomas H.;Timsit S.;Topkis R.;Torosoff M.;Touze E.;Traissac T.;Trendafilova E.;Troyan B.;Tsai W. K.;Tse H. F.;Tsutsui H.;Tsutsui T.;Tuininga Y. S.;Turakhia M.;Turk S.;Turner W.;Tveit A.;Twiddy S.;Tytus R.;Ukrainski G.;Valdovinos Chavez S. B.;Van De Graaff E.;Vanacker P.;Vardas P.;Vargas M.;Vassilikos V.;Vazquez J.;Venkataraman A.;Verdecchia P.;Vester E. G.;Vial H.;Vinereanu D.;Vlastaris A.;Vogel C.;vom Dahl J.;von Mering M.;Vora K.;Wakefield P.;Walia J.;Walter T.;Wang M.;Wang N.;Wang F.;Wang X.;Wang Z.;Wang K. -Y.;Watanabe K.;Wei J.;Weimar C.;Weinrich R.;Wen M. -S.;Wheelan K.;Wicke J.;Wiemer M.;Wild B.;Wilke A.;Willems S.;Williams M.;Williams D.;Winkler A.;Wirtz J. H.;Witzenbichler B.;Wong D. H. K.;Lawrence Wong K. S.;Wong B.;Wozakowska-Kaplon B.;Wu Z.;Wu S.;Wyatt N.;Xu Y.;Xu X.;Yamada A.;Yamamoto K.;Yamanoue H.;Yamashita T.;Bryan Yan P. Y.;Yang Y.;Yang T.;Yao J.;Yarlagadda C.;Yeh K. -H.;Yotov Y.;Yvorra S.;Zahn R.;Zamorano J.;Zanini R.;Zarich S.;Zebrack J.;Zenin S.;Zeuthen E. L.;Zhang X.;Zhang Q.;Zhang D.;Zhang D.;Zhang H.;Zhao S.;Zhao X.;Zheng Y.;Zheng Q.;Zhou J.;Zhou J.;Zimmermann S. L.;Zimmermann R.;Zukerman L. S.;Zwaan van der C.
2017-01-01
Abstract
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701)
Huisman, M. V.; Rothman, K. J.; Paquette, M.; Teutsch, C.; Diener, H. -C.; Dubner, S. J.; Halperin, J. L.; Ma, C. S.; Zint, K.; Elsaesser, A.; Bartels...espandi
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2098277
Attenzione
L'Ateneo sottopone a validazione solo i file PDF allegati
Citazioni
ND
258
241
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
